|
humans |
55 |
|
covid-19 |
52 |
|
influenza |
47 |
|
coronavirus |
44 |
|
sars-cov-2 |
44 |
|
adult |
36 |
|
male |
36 |
|
hong kong - epidemiology |
35 |
|
female |
34 |
|
child |
29 |
|
adolescent |
28 |
|
animals |
28 |
|
molecular sequence data |
28 |
|
hong kong |
27 |
|
middle aged |
27 |
|
aged |
26 |
|
reverse transcriptase polymerase chain reaction |
26 |
|
viral load |
26 |
|
antibodies, viral - blood |
25 |
|
child, preschool |
23 |
|
disease outbreaks |
23 |
|
rna, viral - genetics |
23 |
|
serology |
23 |
|
transmission |
23 |
|
infant |
22 |
|
mouse |
20 |
|
seasons |
20 |
|
china - epidemiology |
19 |
|
animal |
18 |
|
cohort studies |
18 |
|
genome, viral |
18 |
|
influenza virus |
18 |
|
pandemic |
18 |
|
severe acute respiratory syndrome |
18 |
|
aged, 80 and over |
17 |
|
china |
17 |
|
feces - virology |
17 |
|
hospitalization |
17 |
|
interferon |
17 |
|
phylogeny |
17 |
|
sequence analysis, dna |
17 |
|
vaccine |
17 |
|
young adult |
17 |
|
children |
16 |
|
influenza vaccine |
16 |
|
molecular epidemiology |
16 |
|
respiratory tract infections |
16 |
|
sars |
16 |
|
seroepidemiologic studies |
16 |
|
antibody titer |
15 |
|
bat |
15 |
|
epidemiology |
15 |
|
influenza a virus, h1n1 subtype - genetics |
15 |
|
influenza, human - epidemiology - virology |
15 |
|
mask |
15 |
|
risk factors |
15 |
|
sars coronavirus |
15 |
|
zika |
15 |
|
2009 h1n1 influenza |
14 |
|
asymptomatic |
14 |
|
cell line |
14 |
|
disease outbreaks - statistics & numerical data |
14 |
|
enzyme-linked immunosorbent assay |
14 |
|
flavivirus |
14 |
|
genetic predisposition to disease |
14 |
|
h7n9 |
14 |
|
immunity |
14 |
|
mutation |
14 |
|
nasopharynx - virology |
14 |
|
oseltamivir |
14 |
|
polymerase chain reaction |
14 |
|
ace2 |
13 |
|
adaptation |
13 |
|
age |
13 |
|
antibodies, neutralizing - blood |
13 |
|
base sequence |
13 |
|
cytokine and chemokine response |
13 |
|
evolution, molecular |
13 |
|
hemagglutination inhibition tests |
13 |
|
mers-cov |
13 |
|
nucleocapsid proteins - genetics - immunology |
13 |
|
pathogenesis |
13 |
|
rnai |
13 |
|
sace2 |
13 |
|
sars-cov |
13 |
|
treatment |
13 |
|
viral replication |
13 |
|
virus shedding |
13 |
|
adenovirus |
12 |
|
chinese |
12 |
|
chiroptera - virology |
12 |
|
false positive |
12 |
|
influenza a virus, h1n1 subtype - isolation and purification |
12 |
|
influenza, human - diagnosis - virology |
12 |
|
intradermal |
12 |
|
kawasaki disease |
12 |
|
time factors |
12 |
|
amino acid substitution |
11 |
|
animal cell |
11 |
|
animal tissue |
11 |
|
antiviral agents - chemical synthesis - chemistry - pharmacology |
11 |
|
carboxypeptidases - antagonists & inhibitors - metabolism |
11 |
|
cell adhesion molecules - genetics - metabolism |
11 |
|
cercopithecus aethiops |
11 |
|
cho cells - virology |
11 |
|
contamination |
11 |
|
coronavirus disease 2019 |
11 |
|
cricetinae |
11 |
|
cricetulus |
11 |
|
feces analysis |
11 |
|
genotype |
11 |
|
h1n1 |
11 |
|
homozygote |
11 |
|
influenza a virus, h1n1 subtype - genetics - immunology - isolation and purification |
11 |
|
influenza, human - epidemiology - pathology - virology |
11 |
|
intestine, small - physiology |
11 |
|
lectins, c-type - genetics - metabolism |
11 |
|
lung - physiology - virology |
11 |
|
mortality |
11 |
|
murine |
11 |
|
n501y |
11 |
|
neutralization tests |
11 |
|
neutralizing antibody |
11 |
|
pharynx - virology |
11 |
|
proteasome endopeptidase complex - metabolism |
11 |
|
rat |
11 |
|
receptors, cell surface - genetics - metabolism |
11 |
|
sars virus - drug effects - growth & development - metabolism - physiology |
11 |
|
sars virus - metabolism - pathogenicity |
11 |
|
sars-cov-2 variants |
11 |
|
sensitivity and specificity |
11 |
|
severe acute respiratory syndrome - drug therapy |
11 |
|
severe acute respiratory syndrome - epidemiology - genetics |
11 |
|
species index: animalia |
11 |
|
stool |
11 |
|
susceptibility |
11 |
|
tandem repeat sequences |
11 |
|
urine - virology |
11 |
|
vero cells - virology |
11 |
|
viral matrix proteins - antagonists & inhibitors - metabolism |
11 |
|
virus cultivation |
11 |
|
acute disease |
10 |
|
amino acid sequence |
10 |
|
antigen-presentation |
10 |
|
antiviral agents - pharmacology |
10 |
|
blotting, western |
10 |
|
coronavirus - classification - genetics |
10 |
|
coronavirus - genetics - isolation & purification |
10 |
|
coronavirus - immunology - pathogenicity - physiology |
10 |
|
coronavirus infections - immunology - virology |
10 |
|
covid19 |
10 |
|
cytokines - biosynthesis - immunology |
10 |
|
cytokines - blood |
10 |
|
d222g |
10 |
|
d225g |
10 |
|
damplicon |
10 |
|
diagnosis |
10 |
|
diagnostics |
10 |
|
disease reservoirs - virology |
10 |
|
genetic variation |
10 |
|
hemagglutinin |
10 |
|
hemagglutinin glycoproteins, influenza virus - genetics - metabolism |
10 |
|
immunoglobulin g - blood |
10 |
|
incidence |
10 |
|
influenza a virus, h1n1 subtype - genetics - pathogenicity |
10 |
|
influenza a virus, h1n1 subtype - immunology - pathogenicity |
10 |
|
influenza vaccines - immunology |
10 |
|
influenza, human - immunology - pathology - virology |
10 |
|
microscopy, electron |
10 |
|
mutation - genetics |
10 |
|
olfactory dysfunction |
10 |
|
picornaviridae - chemistry - classification - genetics - isolation and purification |
10 |
|
pneumonia |
10 |
|
pneumonia, viral - immunology - virology |
10 |
|
reverse transcriptase polymerase chain reaction - methods |
10 |
|
rna, viral - genetics - isolation & purification |
10 |
|
rt-pcr |
10 |
|
sars virus - isolation & purification |
10 |
|
seasonality |
10 |
|
severe acute respiratory syndrome - diagnosis |
10 |
|
severe acute respiratory syndrome - diagnosis - virology |
10 |
|
sialic acid |
10 |
|
virus |
10 |
|
virus replication - physiology |
10 |
|
5' untranslated regions |
9 |
|
airborne |
9 |
|
airborne infection |
9 |
|
anosmia |
9 |
|
antibodies, viral - biosynthesis |
9 |
|
antibody detection |
9 |
|
antigens, viral - analysis |
9 |
|
bioaerosols |
9 |
|
blood donors |
9 |
|
bocavirus - classification - genetics - isolation and purification |
9 |
|
celecoxib |
9 |
|
chemicals and cas registry numbers |
9 |
|
coronavirus infections - genetics |
9 |
|
cross infection - epidemiology - immunology |
9 |
|
dogs - virology |
9 |
|
illumina sequencing |
9 |
|
immunoglobulin g - analysis - immunology |
9 |
|
influenza a virus, h1n1 subtype - genetics - isolation and purification - physiology |
9 |
|
influenza-virus |
9 |
|
lipidomics |
9 |
|
membrane glycoproteins - analysis |
9 |
|
mesalazine |
9 |
|
model |
9 |
|
operating rooms |
9 |
|
orchitis |
9 |
|
orthomyxoviridae infections - immunology - mortality - physiopathology - virology |
9 |
|
parvoviridae infections - veterinary - virology |
9 |
|
phosphatidic acid phosphatases |
9 |
|
pneumonia, viral - epidemiology - immunology - virology |
9 |
|
pneumonia, viral - virology |
9 |
|
point-of-care testing |
9 |
|
polymorphism, genetic |
9 |
|
public health |
9 |
|
recombinant proteins - analysis - immunology |
9 |
|
recombination, genetic |
9 |
|
rhinovirus |
9 |
|
ribosomes - genetics - metabolism |
9 |
|
risk assessment |
9 |
|
saliva |
9 |
|
sars virus |
9 |
|
sars virus - genetics - isolation & purification |
9 |
|
severe acute respiratory syndrome - epidemiology - immunology - virology |
9 |
|
severe acute respiratory syndrome - epidemiology - transmission - virology |
9 |
|
severe acute respiratory syndrome - virology |
9 |
|
severity of illness index |
9 |
|
smell impairment |
9 |
|
steroid |
9 |
|
t-lymphocytes - immunology |
9 |
|
temperature |
9 |
|
testis |
9 |
|
vaccination |
9 |
|
viral envelope proteins - analysis |
9 |
|
virus replication |
9 |
|
zanamivir |
9 |
|
a(h3n2) |
8 |
|
age factors |
8 |
|
animal experiment |
8 |
|
antibodies, viral - blood - immunology |
8 |
|
antibody blood level |
8 |
|
antibody formation |
8 |
|
antibody response |
8 |
|
asymptomatic infection |
8 |
|
autopsy |
8 |
|
avian influenza virus |
8 |
|
bioaerosol |
8 |
|
canada - epidemiology |
8 |
|
case study |
8 |
|
chemokine |
8 |
|
chicken |
8 |
|
clarithromycin |
8 |
|
cluster analysis |
8 |
|
comorbidity |
8 |
|
conjunctiva |
8 |
|
coronavirus - classification - genetics - isolation & purification |
8 |
|
coronavirus infections - epidemiology - physiopathology - virology |
8 |
|
covid‐19 |
8 |
|
cytokine |
8 |
|
cytokines - genetics - metabolism |
8 |
|
databases, nucleic acid - statistics & numerical data |
8 |
|
diagnostic |
8 |
|
diagnostic test evaluation |
8 |
|
dialysis |
8 |
|
ganglioside gm1 antibody |
8 |
|
hamster |
8 |
|
hepatitis b vaccination |
8 |
|
hospitalization - statistics and numerical data |
8 |
|
hospitalized |
8 |
|
human |
8 |
|
human exhaled breath |
8 |
|
il-8 |
8 |
|
incidence rates |
8 |
|
influenza a virus - isolation & purification |
8 |
|
influenza a virus, h1n1 subtype - genetics - isolation & purification - physiology |
8 |
|
influenza a virus, h1n1 subtype - immunology |
8 |
|
influenza a virus, h1n1 subtype - isolation & purification - pathogenicity |
8 |
|
influenza, human - epidemiology |
8 |
|
influenza, human - epidemiology - transmission - virology |
8 |
|
influenza, human - immunology |
8 |
|
injections, intramuscular |
8 |
|
interferon lambda 1 |
8 |
|
myocarditis |
8 |
|
nanopore sequencing |
8 |
|
naproxen |
8 |
|
nsp1 |
8 |
|
nucleic acid amplification techniques - methods |
8 |
|
pediatric |
8 |
|
real-time rt-pcr |
8 |
|
respiratory system - virology |
8 |
|
respiratory tract infections - epidemiology - physiopathology - virology |
8 |
|
respiratory virus |
8 |
|
rt‐pcr |
8 |
|
sars virus - genetics |
8 |
|
sars‐cov‐2 |
8 |
|
seizures, febrile - epidemiology |
8 |
|
serial |
8 |
|
shedding |
8 |
|
singapore - epidemiology |
8 |
|
spike mutant |
8 |
|
spike s1/s2 mutant |
8 |
|
stem cells |
8 |
|
tlr7 agonist |
8 |
|
urine |
8 |
|
vietnam - epidemiology |
8 |
|
viral load - physiology |
8 |
|
adjuvant |
7 |
|
antibodies, monoclonal - diagnostic use |
7 |
|
antibody |
7 |
|
antiviral |
7 |
|
antiviral agents - administration and dosage - therapeutic use |
7 |
|
antiviral compounds |
7 |
|
astroviridae - classification - genetics - isolation and purification |
7 |
|
astroviridae infections - epidemiology - veterinary - virology |
7 |
|
avian influenza a/h7n9 virus |
7 |
|
bayes theorem |
7 |
|
biopsy |
7 |
|
bird diseases - virology |
7 |
|
bocavirus - classification - genetics - isolation & purification |
7 |
|
bromocriptine |
7 |
|
caco-2 |
7 |
|
cats |
7 |
|
cattle diseases - virology |
7 |
|
cell culture |
7 |
|
chlorogenic acid - chemistry - pharmacology |
7 |
|
clade |
7 |
|
common cold - genetics |
7 |
|
common cold - virology |
7 |
|
community-acquired-infections-epidemiology |
7 |
|
community-acquired-infections-mortality |
7 |
|
community-acquired-infections-physiopathology |
7 |
|
community-acquired-infections-virology |
7 |
|
coronaviridae - classification - genetics - isolation and purification |
7 |
|
coronaviridae infections - veterinary - virology |
7 |
|
coronavirus - immunology |
7 |
|
coronavirus 229e, human - genetics - physiology |
7 |
|
coronavirus infections - virology |
7 |
|
coronavirus oc43, human - classification - genetics - isolation and purification |
7 |
|
coronavirus-genetics |
7 |
|
defective interfering viral genome |
7 |
|
disease severity |
7 |
|
drug synergism |
7 |
|
enterovirus d68 |
7 |
|
enzyme-linked immunosorbent assay - methods |
7 |
|
epidemics |
7 |
|
epidemiology, molecular |
7 |
|
etiology |
7 |
|
evaluation |
7 |
|
fecal |
7 |
|
flavonoids - chemistry - pharmacology |
7 |
|
gastroenteritis |
7 |
|
gastroenteritis - epidemiology - physiopathology - virology |
7 |
|
glycyrrhizic acid - chemistry - pharmacology |
7 |
|
hemagglutinins - genetics |
7 |
|
high infection rate |
7 |
|
human herpesvirus 6b |
7 |
|
icu patient |
7 |
|
immunogenicity |
7 |
|
infant, newborn |
7 |
|
infectivity |
7 |
|
influenza b virus |
7 |
|
influenza, human - drug therapy - epidemiology - virology |
7 |
|
interferon-alpha - pharmacology |
7 |
|
interferon-beta - pharmacology |
7 |
|
lightmix e-gene |
7 |
|
lopinavir |
7 |
|
mammals - virology |
7 |
|
medical sciences |
7 |
|
membrane glycoproteins - genetics - immunology |
7 |
|
mice |
7 |
|
microbial sensitivity tests |
7 |
|
middle east respiratory syndrome |
7 |
|
miltefosine |
7 |
|
multigene family |
7 |
|
nasopharynx/virology |
7 |
|
nose - virology |
7 |
|
nucleocapsid - analysis |
7 |
|
nucleoprotein |
7 |
|
orthomyxoviridae - isolation & purification |
7 |
|
oseltamivir - administration and dosage - therapeutic use |
7 |
|
parvoviridae infections - epidemiology - physiopathology - virology |
7 |
|
parvovirinae - classification - genetics - isolation and purification |
7 |
|
parvovirus - classification - genetics - isolation and purification |
7 |
|
phylodynamic |
7 |
|
phylogenetic |
7 |
|
prospective studies |
7 |
|
protease |
7 |
|
pyrimidinones - pharmacology |
7 |
|
recombination |
7 |
|
reinfection |
7 |
|
reproducibility of results |
7 |
|
respiratory tract infections - epidemiology - virology |
7 |
|
respiratory tract infections - virology |
7 |
|
respiratory viruses |
7 |
|
rhinovirus - classification - genetics |
7 |
|
ribavirin - pharmacology |
7 |
|
rimantadine - pharmacology |
7 |
|
rodent diseases - virology |
7 |
|
route of transmission |
7 |
|
sars cov |
7 |
|
sars virus - chemistry |
7 |
|
sars virus - classification - genetics - isolation & purification |
7 |
|
sars virus - drug effects |
7 |
|
sars virus - genetics - physiology |
7 |
|
sars virus - immunology |
7 |
|
sars virus - isolation and purification |
7 |
|
sars-coronavirus seroprevalence |
7 |
|
severe acute respiratory syndrome - blood - epidemiology |
7 |
|
severe acute respiratory syndrome - blood - physiopathology - urine - virology |
7 |
|
severe acute respiratory syndrome - genetics |
7 |
|
single molecule real time sequencing |
7 |
|
single-tube nested |
7 |
|
small-molecule inhibitor |
7 |
|
stability |
7 |
|
swine |
7 |
|
tfh |
7 |
|
untranslated |
7 |
|
viral envelope proteins - genetics - immunology |
7 |
|
viral genome |
7 |
|
viral isolation |
7 |
|
viral plaque assay |
7 |
|
viral proteins - blood - genetics |
7 |
|
viral shedding |
7 |
|
2019 novel coronavirus |
6 |
|
25-hydroxyvitamin d |
6 |
|
3' untranslated regions |
6 |
|
acute respiratory illness |
6 |
|
administration, oral |
6 |
|
amino acid substitution - genetics |
6 |
|
animals, domestic |
6 |
|
antibody assay |
6 |
|
antibody specificity |
6 |
|
antigen |
6 |
|
asia - epidemiology |
6 |
|
australasia - epidemiology |
6 |
|
automated |
6 |
|
bacterial vaccines - administration & dosage - immunology |
6 |
|
bile |
6 |
|
biliary |
6 |
|
bird diseases - epidemiology - virology |
6 |
|
broad-spectrum |
6 |
|
bronchi - pathology |
6 |
|
cancer |
6 |
|
carcinoma |
6 |
|
cat diseases - virology |
6 |
|
cell nucleus - ultrastructure |
6 |
|
cholangiocarcinoma |
6 |
|
cholangitis |
6 |
|
cohort |
6 |
|
coinfection |
6 |
|
coronaviridae - classification - genetics - isolation & purification |
6 |
|
coronavirus - classification - isolation & purification - ultrastructure |
6 |
|
coronavirus infections - diagnosis - transmission - virology |
6 |
|
cost |
6 |
|
cox model |
6 |
|
cross protection |
6 |
|
crossing over, genetic |
6 |
|
demography |
6 |
|
detection |
6 |
|
diagnostic assay |
6 |
|
disease progression |
6 |
|
disease transmission |
6 |
|
dna, viral - classification - genetics |
6 |
|
early diagnosis |
6 |
|
elderly |
6 |
|
elisa |
6 |
|
emerging |
6 |
|
enterovirus a, human - classification - genetics - isolation & purification |
6 |
|
envelope |
6 |
|
escherichia coli proteins |
6 |
|
europe - epidemiology |
6 |
|
evolution |
6 |
|
family characteristics |
6 |
|
fatal outcome |
6 |
|
fever - diagnosis |
6 |
|
flow cytometry |
6 |
|
fluorescent antibody technique, indirect |
6 |
|
gastroenteritis - epidemiology - virology |
6 |
|
genes, viral/ - genetics |
6 |
|
genome |
6 |
|
genome subtraction |
6 |
|
giant cells - ultrastructure |
6 |
|
guanosine |
6 |
|
hand, foot and mouth disease - epidemiology - virology |
6 |
|
hemagglutinins, viral - metabolism |
6 |
|
host-targeted antiviral |
6 |
|
hpyv6 |
6 |
|
human adenovirus |
6 |
|
human rhinovirus |
6 |
|
human rhinovirus c |
6 |
|
imiquimod |
6 |
|
immunization schedule |
6 |
|
immunization, secondary |
6 |
|
immunohistochemistry |
6 |
|
infection |
6 |
|
infectiousness |
6 |
|
influenza a virus, h1n1 subtype - metabolism |
6 |
|
influenza a virus, h3n2 subtype - genetics - physiology |
6 |
|
influenza a virus, h5n1 subtype - classification - genetics |
6 |
|
influenza b |
6 |
|
influenza in birds - diagnosis - genetics - virology |
6 |
|
influenza in birds - epidemiology - transmission - virology |
6 |
|
influenza vaccines - administration & dosage - immunology |
6 |
|
influenza, human - complications - diagnosis - epidemiology |
6 |
|
influenza, human - complications - epidemiology |
6 |
|
influenza, human - diagnosis - genetics - virology |
6 |
|
influenza, human - epidemiology - prevention & control - virology |
6 |
|
influenza, human - virology |
6 |
|
injections, intraperitoneal |
6 |
|
intensive care unit |
6 |
|
interferon-gamma - analysis |
6 |
|
interleukin-4 - analysis |
6 |
|
intra-host diversity |
6 |
|
isolation |
6 |
|
lung - pathology - virology |
6 |
|
macrophages - immunology - virology |
6 |
|
malignancy |
6 |
|
membrane glycoproteins - administration & dosage - genetics - immunology |
6 |
|
mers coronavirus |
6 |
|
metaplasia |
6 |
|
metapneumovirus - isolation & purification |
6 |
|
mice, inbred balb c |
6 |
|
models, animal |
6 |
|
models, biological |
6 |
|
models, genetic |
6 |
|
molecular diagnostic techniques - methods |
6 |
|
molecular modelling |
6 |
|
morbidity |
6 |
|
morbillivirus - pathogenicity |
6 |
|
multigene family - genetics |
6 |
|
mycobacterium tuberculosis |
6 |
|
nasal cavity - virology |
6 |
|
nasopharyngeal |
6 |
|
nasopharyngeal swab |
6 |
|
nephritis, interstitial - virology |
6 |
|
new york - epidemiology |
6 |
|
next-generation sequencing |
6 |
|
novel |
6 |
|
novobiocin |
6 |
|
nsp2 |
6 |
|
nucleic acid conformation |
6 |
|
nucleocapsid proteins - analysis |
6 |
|
nucleocapsid proteins - immunology |
6 |
|
nucleocapsid proteins - isolation & purification |
6 |
|
open reading frames - genetics |
6 |
|
opportunistic infections - diagnosis - transmission - virology |
6 |
|
organ size |
6 |
|
outbreak |
6 |
|
pandemics |
6 |
|
parainfluenza virus 4, human - classification - genetics - isolation & purification |
6 |
|
paramyxoviridae - classification - genetics - isolation & purification |
6 |
|
paramyxoviridae infections - diagnosis - epidemiology - virology |
6 |
|
paramyxoviridae infections - veterinary - virology |
6 |
|
paramyxovirus |
6 |
|
pcr |
6 |
|
phylogeography |
6 |
|
picornaviridae - classification - genetics - isolation & purification |
6 |
|
picornaviridae infections - epidemiology - virology |
6 |
|
placebos - administration & dosage |
6 |
|
pneumocytis |
6 |
|
pneumonia - etiology |
6 |
|
polymerase inhibitor |
6 |
|
polyomavirus |
6 |
|
pooling |
6 |
|
population dynamics |
6 |
|
poultry - virology |
6 |
|
premembrane |
6 |
|
quantitative rt-pcr |
6 |
|
real time rt-pcr |
6 |
|
real-time pcr |
6 |
|
realstar® adenovirus pcr kit |
6 |
|
respiratory |
6 |
|
respiratory syncytial virus |
6 |
|
respiratory syncytial virus infections - diagnosis - epidemiology - virology |
6 |
|
respiratory syncytial viruses - isolation & purification |
6 |
|
respiratory tract infection |
6 |
|
respiratory tract infections - diagnosis - epidemiology - virology |
6 |
|
reverse transcriptase polymerase chain reaction - methods - standards |
6 |
|
rhinovirus - classification - genetics - isolation and purification |
6 |
|
rna, viral - analysis |
6 |
|
rna, viral - analysis - isolation & purification |
6 |
|
rna, viral - chemistry |
6 |
|
sars virus - classification - genetics |
6 |
|
sars virus - genetics - immunology - isolation & purification |
6 |
|
sars virus - pathogenicity |
6 |
|
sars virus - physiology |
6 |
|
seizure |
6 |
|
sequence alignment |
6 |
|
sequence homology, amino acid |
6 |
|
severe acute respiratory syndrome - complications - immunology |
6 |
|
severe acute respiratory syndrome - complications - pathology - virology |
6 |
|
severe acute respiratory syndrome - diagnosis - immunology |
6 |
|
severe acute respiratory syndrome - diagnosis - immunology - virology |
6 |
|
severe acute respiratory syndrome - diagnosis - transmission - virology |
6 |
|
severe acute respiratory syndrome - diagnosis - urine |
6 |
|
severe acute respiratory syndrome - epidemiology - microbiology |
6 |
|
severe acute respiratory syndrome - epidemiology - virology |
6 |
|
severe acute respiratory syndrome - immunology - virology |
6 |
|
severe acute respiratory syndrome - mortality - physiopathology - virology |
6 |
|
severe acute respiratory syndrome - prevention & control |
6 |
|
smoking |
6 |
|
songbirds - virology |
6 |
|
source-sink |
6 |
|
species specificity |
6 |
|
specimen handling |
6 |
|
tract |
6 |
|
tropical climate |
6 |
|
tuhokovirus |
6 |
|
vaccination - methods |
6 |
|
vaccines, dna - administration & dosage - immunology |
6 |
|
vaccines, inactivated - administration & dosage - immunology |
6 |
|
vaccines, synthetic - administration & dosage - immunology |
6 |
|
victoria lineage |
6 |
|
viral envelope proteins - administration & dosage - genetics - immunology |
6 |
|
viral proteins - genetics |
6 |
|
viral proteins - genetics - metabolism |
6 |
|
viral structural proteins - genetics |
6 |
|
viremia - diagnosis - epidemiology |
6 |
|
virology - methods |
6 |
|
whole-genome sequencing |
6 |
|
yamagata lineage |
6 |
|
zoonoses - epidemiology |
6 |
|
actins - genetics |
5 |
|
adaptation, biological |
5 |
|
aichi virus |
5 |
|
alere i flu a & b |
5 |
|
animals, domestic - virology |
5 |
|
anti-bacterial agents - pharmacology - therapeutic use |
5 |
|
antibiotic prophylaxis |
5 |
|
antibody affinity |
5 |
|
antiviral agents - therapeutic use |
5 |
|
arthralgia |
5 |
|
avian influenza |
5 |
|
b.1.1.7b.1.351 |
5 |
|
bats |
5 |
|
bk virus - isolation & purification - physiology |
5 |
|
broad-spectrum antivirals |
5 |
|
burden |
5 |
|
calibration |
5 |
|
children. |
5 |
|
chinese horseshoe bats |
5 |
|
ciprofloxacin - pharmacology - therapeutic use |
5 |
|
community-acquired infections |
5 |
|
controlled study |
5 |
|
coronaviridae - chemistry - classification - genetics - isolation and purification |
5 |
|
cross infection - diagnosis - epidemiology - virology |
5 |
|
cytokines |
5 |
|
diversity |
5 |
|
dna primers |
5 |
|
dna, complementary - analysis |
5 |
|
dna, protozoan - blood - genetics |
5 |
|
dna, ribosomal - analysis |
5 |
|
dna, viral - chemistry - genetics |
5 |
|
dog diseases - virology |
5 |
|
drug dosage form comparison |
5 |
|
drug dose comparison |
5 |
|
enterovirus - classification - genetics - isolation and purification |
5 |
|
epstein-barr virus |
5 |
|
family health |
5 |
|
genetic variation - genetics |
5 |
|
h5n1 |
5 |
|
h9n2 |
5 |
|
haplorhini |
5 |
|
hematopoietic stem cell transplantation - adverse effects |
5 |
|
herpes simplex virus 2 |
5 |
|
herpesviridae |
5 |
|
hku2 |
5 |
|
hot temperature |
5 |
|
human alphaherpesvirus 1 |
5 |
|
human coronaviruses |
5 |
|
human parechovirus |
5 |
|
immunoglobulins |
5 |
|
infectious disease |
5 |
|
influenza a virus - genetics - isolation & purification |
5 |
|
influenza a virus - physiology |
5 |
|
influenza a virus, h1n1 subtype - genetics - isolation & purification |
5 |
|
influenza a virus, h3n2 subtype - genetics - isolation and purification |
5 |
|
influenza a virus, h7n9 subtype - genetics - isolation and purification |
5 |
|
influenza b virus - physiology |
5 |
|
influenza, human - drug therapy - transmission - virology |
5 |
|
influenza, human - pathology - virology |
5 |
|
intradermal influenza vaccination |
5 |
|
lineage specific |
5 |
|
luminex nxtag |
5 |
|
macrophages |
5 |
|
malaria, falciparum - blood - diagnosis |
5 |
|
membrane glycoproteins - chemistry - genetics |
5 |
|
membrane glycoproteins - genetics |
5 |
|
multiplex real time polymerase chain reaction |
5 |
|
neutralizing antibody spike protein receptor binding domain |
5 |
|
nucleocapsid proteins - genetics |
5 |
|
open reading frames |
5 |
|
origin |
5 |
|
orthomyxoviridae - isolation and purification |
5 |
|
oseltamivir - pharmacology |
5 |
|
oseltamivir - therapeutic use |
5 |
|
outpatient |
5 |
|
picornaviridae - classification - genetics - isolation and purification |
5 |
|
plasmodium falciparum - genetics - isolation & purification |
5 |
|
point-of-care systems |
5 |
|
polymerase chain reaction - economics - methods - standards |
5 |
|
polyomavirus infections - prevention & control - virology |
5 |
|
population susceptibility |
5 |
|
pulmonology |
5 |
|
pyrimidine synthesis inhibitor |
5 |
|
rabbits - virology |
5 |
|
rapid molecular test |
5 |
|
receptor |
5 |
|
recombinant proteins - immunology |
5 |
|
reference standards |
5 |
|
resting-state fmri |
5 |
|
retrospective studies |
5 |
|
rna, ribosomal, 18s - genetics |
5 |
|
rubulavirus infections - diagnosis - epidemiology - virology |
5 |
|
rubulavirus infections - epidemiology - virology |
5 |
|
salivirus |
5 |
|
sars virus - genetics - growth & development - isolation & purification |
5 |
|
sars-cov-2 n501y variant |
5 |
|
selection |
5 |
|
self-examination - methods |
5 |
|
serial passage |
5 |
|
seroprevalence |
5 |
|
severe acute respiratory syndrome - blood - mortality - virology |
5 |
|
smell training |
5 |
|
specimen handling - methods |
5 |
|
swine diseases - virology |
5 |
|
symptom |
5 |
|
symptoms |
5 |
|
transplantation, homologous - adverse effects |
5 |
|
treatment outcome |
5 |
|
triavalent influenza vaccine |
5 |
|
tumor virus infections - prevention & control - virology |
5 |
|
vaccine effectiveness |
5 |
|
viral envelope proteins - chemistry - genetics |
5 |
|
viral envelope proteins - genetics |
5 |
|
viral matrix proteins - genetics |
5 |
|
virus replication - drug effects |
5 |
|
vitamin a |
5 |
|
voc |
5 |
|
xpert xpress flu/rsv |
5 |
|
young infants |
5 |
|
aborted fetus |
4 |
|
accuracy |
4 |
|
age distribution |
4 |
|
anaplasma platys |
4 |
|
anti-bacterial agents - therapeutic use |
4 |
|
antibodies |
4 |
|
antigens, cd55 - genetics - immunology |
4 |
|
asthma - complications |
4 |
|
asthma exacerbation |
4 |
|
azithromycin - therapeutic use |
4 |
|
babesia |
4 |
|
bacterial pneumonia |
4 |
|
birds |
4 |
|
bk virus - isolation & purification |
4 |
|
cardiac complications |
4 |
|
child hospitalization |
4 |
|
children <5 years |
4 |
|
clade a |
4 |
|
coronavirus infections - epidemiology - veterinary - virology |
4 |
|
diagnostic tests |
4 |
|
dirofilaria immitis |
4 |
|
disease burden |
4 |
|
dogs |
4 |
|
dromedary |
4 |
|
dromedary camels |
4 |
|
drug resistance, viral |
4 |
|
effectiveness |
4 |
|
ehrlichia |
4 |
|
epithelial cells - metabolism |
4 |
|
gene expression regulation - immunology |
4 |
|
genotype 6 |
4 |
|
genotyping |
4 |
|
giant panda |
4 |
|
handwashing |
4 |
|
hematopoietic stem cell transplantation - adverse effects - methods |
4 |
|
hepatitis c virus |
4 |
|
hospitalization - statistics & numerical data |
4 |
|
human herpesvirus 6 |
4 |
|
human influenza |
4 |
|
hygiene |
4 |
|
immunoassay |
4 |
|
immunoassay - methods |
4 |
|
immunotherapy - methods |
4 |
|
influenza a virus - genetics - immunology - isolation and purification |
4 |
|
influenza a virus - immunology - isolation and purification |
4 |
|
influenza a virus, h1n1 subtype - drug effects |
4 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
4 |
|
influenza a virus, h3n2 subtype - isolation and purification |
4 |
|
influenza a virus, h5n1 subtype - immunology - pathogenicity |
4 |
|
influenza a(h1n1)pdm09 |
4 |
|
influenza b virus - immunology - isolation and purification |
4 |
|
influenza b virus - isolation & purification |
4 |
|
influenza b virus - isolation and purification |
4 |
|
influenza, human - diagnosis - prevention & control - transmission |
4 |
|
influenza, human - epidemiology - prevention and control - transmission |
4 |
|
influenza, human - genetics - immunology - pathology - virology |
4 |
|
influenza, human - mortality - therapy - virology |
4 |
|
interim |
4 |
|
lower respiratory tract infection |
4 |
|
macrolides - therapeutic use |
4 |
|
macrophages - metabolism - virology |
4 |
|
masks |
4 |
|
masks - statistics and numerical data |
4 |
|
mers |
4 |
|
middle east respiratory syndrome coronavirus |
4 |
|
molecular diagnosis |
4 |
|
molecular typing |
4 |
|
mycoplasma pneumoniae - metabolism |
4 |
|
nasopharyngeal carcinoma |
4 |
|
neuraminidase - antagonists & inhibitors - genetics |
4 |
|
newcastle disease virus |
4 |
|
orthomyxoviridae infections - virology |
4 |
|
pandemic a ⁄ h1n1 |
4 |
|
pandemic h1n1 |
4 |
|
parainfluenza virus |
4 |
|
patient compliance |
4 |
|
patient education as topic |
4 |
|
pediatrics |
4 |
|
picornaviridae infections - diagnosis - epidemiology - physiopathology - virology |
4 |
|
picornaviridae infections - veterinary - virology |
4 |
|
plasma - immunology |
4 |
|
pneumonia - drug therapy - radiography |
4 |
|
polymorphism, single nucleotide |
4 |
|
polyomavirus infections - complications - diagnosis |
4 |
|
polyphyletic |
4 |
|
reagent kits, diagnostic |
4 |
|
realstar® hhv-6 pcr kit |
4 |
|
reassortant viruses - genetics |
4 |
|
respiratory infections |
4 |
|
respiratory syncytial virus infections - epidemiology |
4 |
|
respiratory tract infections - diagnosis - epidemiology - physiopathology - virology |
4 |
|
respiratory tract infections - epidemiology |
4 |
|
rhinovirus - classification - genetics - isolation & purification |
4 |
|
rna, messenger - genetics - metabolism |
4 |
|
sars virus - genetics - immunology |
4 |
|
sensitivity |
4 |
|
sex |
4 |
|
specificity |
4 |
|
synteny |
4 |
|
united arab emirates |
4 |
|
wolbachia |
4 |
|
acute respiratory tract disease |
3 |
|
adenoviridae infections - epidemiology - pathology |
3 |
|
adenoviruses, human - isolation and purification |
3 |
|
antibodies, bacterial - immunology |
3 |
|
antibodies, monoclonal - immunology |
3 |
|
antibodies, viral - biosynthesis - blood |
3 |
|
antibodies, viral - chemistry |
3 |
|
antibodies, viral - isolation & purification |
3 |
|
antigens, viral - immunology |
3 |
|
asthma |
3 |
|
biological markers |
3 |
|
ca-mrsa |
3 |
|
carcinoma - diagnosis - epidemiology - immunology - virology |
3 |
|
carcinoma - pathology - virology |
3 |
|
case-control studies |
3 |
|
cell-based receptor binding assay |
3 |
|
chinese children |
3 |
|
chromatography - methods |
3 |
|
cost of illness |
3 |
|
dna vaccine |
3 |
|
dna, viral - isolation & purification |
3 |
|
dna-binding proteins - immunology |
3 |
|
drug resistance, viral - genetics |
3 |
|
ebv antibody |
3 |
|
ebv serology |
3 |
|
epstein-barr virus infections - complications - diagnosis |
3 |
|
epstein-barr virus infections - epidemiology - immunology |
3 |
|
epstein-barr virus nuclear antigens - immunology |
3 |
|
erythema - epidemiology - immunology |
3 |
|
escherichia coli proteins - immunology |
3 |
|
exacerbations |
3 |
|
facility design and construction |
3 |
|
generalized cross validation |
3 |
|
h275y |
3 |
|
health hazard |
3 |
|
hemagglutinins - chemistry |
3 |
|
herpesvirus 4, human - genetics - immunology - isolation & purification |
3 |
|
herpesvirus 4, human - immunology |
3 |
|
hospitalization - economics |
3 |
|
hospitalization disease burden |
3 |
|
housing |
3 |
|
immunocompetence |
3 |
|
immunoglobulin a - blood - immunology |
3 |
|
immunoglobulin g - blood - immunology |
3 |
|
in situ hybridization |
3 |
|
infectious mononucleosis |
3 |
|
infectious mononucleosis - physiopathology - virology |
3 |
|
influenza a virus, h1n1 subtype - drug effects - genetics - immunology |
3 |
|
influenza a virus, h1n1 subtype - pathogenicity |
3 |
|
influenza a virus, h3n2 subtype - pathogenicity |
3 |
|
influenza a virus, h5n1 subtype - immunology |
3 |
|
influenza vaccines - administration & dosage - adverse effects - immunology |
3 |
|
influenza vaccines - economics |
3 |
|
influenza, human - blood - immunology - virology |
3 |
|
influenza, human - complications - diagnosis - epidemiology - therapy |
3 |
|
influenza, human - economics - epidemiology |
3 |
|
influenza, human - mortality |
3 |
|
injections, intradermal |
3 |
|
intermethod comparison |
3 |
|
lineage differentiation |
3 |
|
metapneumovirus - pathogenicity |
3 |
|
mice, inbred balb/c |
3 |
|
multiplex pcr |
3 |
|
nasopharyngeal neoplasms - diagnosis - epidemiology - immunology - virology |
3 |
|
nasopharyngeal neoplasms - pathology - virology |
3 |
|
neoplasm recurrence, local - virology |
3 |
|
neoplasm staging |
3 |
|
neuraminidase |
3 |
|
neuraminidase - genetics - immunology - metabolism |
3 |
|
npc |
3 |
|
npc diagnosis |
3 |
|
npc risk |
3 |
|
odds ratio |
3 |
|
orthomyxoviridae infections - immunology |
3 |
|
pain - epidemiology - immunology |
3 |
|
pandemics - statistics and numerical data |
3 |
|
paramyxoviridae infections - epidemiology - pathology |
3 |
|
paramyxoviridae infections - physiopathology - virology |
3 |
|
poisson distribution |
3 |
|
polymerase chain reaction - methods |
3 |
|
population-based |
3 |
|
predictive value of tests |
3 |
|
reduced dosage |
3 |
|
regression analysis |
3 |
|
resistance |
3 |
|
respiratory syncytial virus infections - epidemiology - pathology |
3 |
|
risk |
3 |
|
sars virus - immunology - isolation & purification |
3 |
|
serologic tests - methods |
3 |
|
serologic tests - standards |
3 |
|
serotypes |
3 |
|
severe acute respiratory syndrome - blood - diagnosis |
3 |
|
severe acute respiratory syndrome - blood - diagnosis - immunology |
3 |
|
socioeconomic burden |
3 |
|
spike glycoprotein |
3 |
|
spike protein |
3 |
|
swine origin influenza virus a/h1n1 |
3 |
|
trans-activators - immunology |
3 |
|
trigger |
3 |
|
tumor burden |
3 |
|
tumor marker |
3 |
|
tumor markers, biological - analysis |
3 |
|
urban population |
3 |
|
vaccination - adverse effects |
3 |
|
victoria |
3 |
|
viral infection |
3 |
|
viral proteins |
3 |
|
viral proteins - genetics - immunology - metabolism |
3 |
|
virus neutralization |
3 |
|
yamagata |
3 |
|
amino acids - genetics - immunology |
2 |
|
antibodies, monoclonal - genetics - immunology |
2 |
|
antigenic sites |
2 |
|
antigenic variation |
2 |
|
asymptomatic primary infection |
2 |
|
b cells. |
2 |
|
cell line, tumor |
2 |
|
cell membrane - metabolism |
2 |
|
clinical effectiveness |
2 |
|
clinical feature |
2 |
|
compartment model |
2 |
|
contact examination |
2 |
|
coronavirus 229e, human - metabolism |
2 |
|
coronavirus infections - metabolism |
2 |
|
crystallography, x-ray |
2 |
|
dna, viral - analysis |
2 |
|
ebv |
2 |
|
epitope mapping |
2 |
|
epitopes - chemistry - genetics - immunology |
2 |
|
epstein-barr virus. |
2 |
|
epstein–barr virus |
2 |
|
evolution analysis |
2 |
|
fluorescent antibody technique |
2 |
|
foot and mouth disease |
2 |
|
gene expression regulation |
2 |
|
ha |
2 |
|
hand |
2 |
|
hemagglutinin glycoproteins, influenza virus - chemistry - genetics - immunology |
2 |
|
herpes zoster |
2 |
|
herpesvirus 4, human |
2 |
|
immunodominance |
2 |
|
immunodominance hierarchies |
2 |
|
immunodominant positions |
2 |
|
in situ |
2 |
|
influenza a virus, h5n1 subtype - genetics - immunology |
2 |
|
live-attenuated |
2 |
|
lupus |
2 |
|
lytic and latent proteins |
2 |
|
microarray analysis - methods |
2 |
|
models, molecular |
2 |
|
mucous membrane - microbiology |
2 |
|
nasopharyngeal neoplasms - immunology - microbiology |
2 |
|
natural killer cells |
2 |
|
nkg2a |
2 |
|
nucleic acid hybridization |
2 |
|
polyfunctional t cells |
2 |
|
post-transplant lymphoproliferative disorder |
2 |
|
protein conformation |
2 |
|
protein structure, tertiary |
2 |
|
safety |
2 |
|
sars virus - metabolism |
2 |
|
severe acute respiratory syndrome - metabolism |
2 |
|
transcription, genetic |
2 |
|
viral diagnosis |
2 |
|
virus culture |
2 |
|
yeasts - genetics - metabolism |
2 |
|
anticardiolipin |
1 |
|
dendritic cells |
1 |
|
dengue virus |
1 |
|
epstein-barr virus (eb病毒) |
1 |
|
lupus anticoagulant |
1 |
|
mutz-3 |
1 |
|
nasopharyngeal neoplasms /etiology (鼻咽腫瘤/病因學) |
1 |
|
serologic detection (血清學檢測) |
1 |
